Literature DB >> 26314773

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

H Tilly1, M Gomes da Silva2, U Vitolo3, A Jack4, M Meignan5, A Lopez-Guillermo6, J Walewski7, M André8, P W Johnson9, M Pfreundschuh10, M Ladetto11.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26314773     DOI： 10.1093/annonc/mdv304

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  191 in total

Review 1.  [Current therapeutic strategies for diffuse large B‑cell lymphoma].

Authors:  M Pfreundschuh
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

2.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Authors:  Andres Forero-Torres; Radhakrishnan Ramchandren; Abdulraheem Yacoub; Michael S Wertheim; William J Edenfield; Paolo Caimi; Martin Gutierrez; Luke Akard; Carolina Escobar; Justin Call; Daniel Persky; Swaminathan Iyer; Douglas J DeMarini; Li Zhou; Xuejun Chen; Fitzroy Dawkins; Tycel J Phillips
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

3.  Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.

Authors:  Pierre Decazes; Stéphanie Becker; Mathieu Nessim Toledano; Pierre Vera; Paul Desbordes; Fabrice Jardin; Hervé Tilly; Isabelle Gardin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-28       Impact factor: 9.236

4.  Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma.

Authors:  Scott F Huntington; Jessica R Hoag; Weiwei Zhu; Rong Wang; Amer M Zeidan; Smith Giri; Nikolai A Podoltsev; Steven D Gore; Xiaomei Ma; Cary P Gross; Amy J Davidoff
Journal:  Cancer       Date:  2018-09-14       Impact factor: 6.860

5.  Recurrent Pancreatitis Secondary to Diffuse Large B Cell Lymphoma.

Authors:  Maham Hayat; Taseen A Syed; Molly Disbrow; Ngoc Thy Bao Tran; Zain Ul Abideen Asad; William M Tierney
Journal:  J Gastrointest Cancer       Date:  2019-12

6.  CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison.

Authors:  Peter Dreger; Sascha Dietrich; Maria-Luisa Schubert; Lorenz Selberg; Andrea Bondong; Mandy Wegner; Peter Stadtherr; Christoph Kimmich; Florentina Kosely; Anita Schmitt; Petra Pavel; Nora Liebers; Thomas Luft; Ute Hegenbart; Aleksandar Radujkovic; Anthony Dick Ho; Carsten Müller-Tidow; Michael Schmitt
Journal:  Blood Adv       Date:  2020-12-22

7.  Delayed diagnosis of sinonasal lymphoma due to bilateral manifestation.

Authors:  Si-Young Kiessling; Michael B Soyka; Gerhard F Huber; David Holzmann; Roman D Laske
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-31       Impact factor: 2.503

8.  A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway.

Authors:  Kang Lu; Bo Li; Hui Zhang; Zhijian Xu; Dongliang Song; Lu Gao; Haiguo Sun; Liping Li; Yingcong Wang; Qilin Feng; Gege Chen; Liangning Hu; Rong Wei; Yongsheng Xie; Dandan Yu; Xiaosong Wu; Weiliang Zhu; Jumei Shi
Journal:  Signal Transduct Target Ther       Date:  2020-04-01

9.  18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome.

Authors:  Anne-Ségolène Cottereau; Christophe Nioche; Anne-Sophie Dirand; Jérôme Clerc; Franck Morschhauser; Olivier Casasnovas; Michel Meignan; Irène Buvat
Journal:  J Nucl Med       Date:  2019-06-14       Impact factor: 10.057

10.  R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience.

Authors:  Sandra Bašić-Kinda; Ivo Radman; Dino Dujmović; Ivana Ilić; Marko Kralik; Margareta Dobrenić; Lea Galunić-Bilić; Pavle Rončević; Marijo Vodanović; Zrinka Sertić; Ida Hude; Igor Aurer
Journal:  Ann Hematol       Date:  2020-11-20       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.